Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data

BACKGROUND: Avapritinib, a potent inhibitor of KIT and platelet-derived growth factor receptor A (PDGFRA) tyrosine kinases, has demonstrated unprecedented clinical activity in PDGFRA D842V-mutant gastrointestinal stromal tumors (GIST). METHODS: This retrospective analysis compared efficacy of avapri...

Descripción completa

Detalles Bibliográficos
Autores principales: von Mehren, Margaret, Heinrich, Michael C., Shi, Hongliang, Iannazzo, Sergio, Mankoski, Raymond, Dimitrijević, Saša, Hoehn, Gerard, Chiroli, Silvia, George, Suzanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7976710/
https://www.ncbi.nlm.nih.gov/pubmed/33740926
http://dx.doi.org/10.1186/s12885-021-08013-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7976710/
https://www.ncbi.nlm.nih.gov/pubmed/33740926
http://dx.doi.org/10.1186/s12885-021-08013-1

Ejemplares similares